利培酮微球和利培酮治疗精神分裂症对照研究  

A comparative study of risperidone long-acting injection and risperidone in treatment for patients with schizophrenia

作　　者：苏磊[1] 孙自豪 冯凡 李龙飞[3] 

机构地区：[1]山东省精神卫生中心,山东济南250014 [2]济南市优抚医院 [3]济宁市精神病防治院

出　　处：《精神医学杂志》2015年第4期267-270,共4页Journal of Psychiatry

摘　　要：目的探寻利培酮微球和利培酮治疗精神分裂症患者的疗效和安全性。方法将160例精神分裂症患者随机分为研究组和对照组各80例,研究组用利培酮微球系统治疗,对照组用利培酮系统治疗,共3个月,在基线和治疗后1、2、3个月末应用阳性和阴性综合征量表(PANSS)、临床疗效总评量表-病情严重程度(CGI-S)、临床疗效总评量表-疗效总评(CGI-I)、锥体外系症状评定量表(ESRS)评价。结果两组在治疗后第1、2、3个月末的PANSS评分均低于基线时相应评分(P<0.05)。在治疗后第2、3个月末,研究组PANSS评分以及CGI评分均低于对照组(P<0.05)。研究组治疗后第1、2、3个月末ESRS评分均低于对照组(P<0.05)。结论利培酮微球可有效、安全地治疗精神分裂症患者。Objective To explore the efficacy and safety of risperidone long-acting injection and risperidone in treatment for patients with schizophrenia.Methods A total of 160 patients with schizophrenia were randomly divided into study group （ 80 cases） with risperidone long-acting injection and control group（80 cases） with risperidone for treatment of 3 months.They were assessed with Positive and Negative Syndrome Scale（PANSS）, Clinical Global Impression-Severity of Illness（CGI-S）, Clinical Global Impression-Global Improvement（CGI-I） and Extrapyramidal Symptom Rating Scale（ESRS） at baseline , 1st month end, 2nd month end and 3rd month end of treatment.Results At 1st month end, 2nd month end and 3rd month end of treatment, the factors and total scores of PANSS in two groups were all significantly lower than those at baseline（P〈0.05）.At 2nd month end and 3rd month end of treatment, the factors and total scores of PANSS and CGI in study group were all significantly lower than those in control group（P〈0.05）.At 1st month end, 2nd month end and 3rd month end of treatment, the scores of ESRS in study group were significantly lower than those in control group（P〈0.05）.Conclusion It’s effective and safe for risperidone long-acting injection to treat the patients with schizophrenia.

关 键 词：利培酮微球 利培酮 精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]